Literature DB >> 28914120

The furthest left behind: the urgent need to scale up harm reduction in prisons.

Gen Sander1, Fionnuala Murphy1.   

Abstract

Purpose Raise awareness about the disproportionate impact of HIV and hepatitis C (HCV) on prisoners worldwide and the need for key harm reduction services such as needle and syringe programmes and opioid substitution therapy in prisons offer practical recommendations to assist policy makers in implementing or scaling up these services. The paper aims to discuss these issues. Design/methodology/approach This study is a desk review of existing data and evidence on HIV, HCV and harm reduction in prisons, analysis of political barriers and formulation of key policy recommendations. Findings Harm reduction works, yet service provision in prisons remains extremely limited. There is an urgent need for governments to enhance political leadership and funding for harm reduction in prisons. Authorities must also work to remove obstacles to the implementation of harm reduction services in prisons, enhance the monitoring and evaluation of laws, policies and programmes relating to HIV, HCV and drugs in prison settings, and recognise access to harm reduction in prisons as a fundamental human right. Until these obstacles are addressed, the world will not meet the Sustainable Development Goal of eradicating HIV and HCV by 2030. Originality/value More than just a desk review, this policy brief provides a political analysis of the harm reduction crisis in prisons and offers clear-cut recommendations for policy makers.

Entities:  

Keywords:  HCV; HIV; Harm reduction; Needle exchange; Opioid substitution therapy; Prison

Mesh:

Year:  2017        PMID: 28914120     DOI: 10.1108/IJPH-08-2016-0044

Source DB:  PubMed          Journal:  Int J Prison Health        ISSN: 1744-9200


  6 in total

1.  Report from the International Viral Hepatitis Elimination Meeting (IVHEM), 17-18 November 2017, Amsterdam, the Netherlands: gaps and challenges in the WHO 2030 hepatitis C elimination framework.

Authors:  Stephanie Popping; Manal El-Sayed; Jordan Feld; Angelos Hatzakis; Margaret Hellard; Olufunmilayo Lesi; Michael Ninburg; John Ward; Charles Boucher
Journal:  J Virus Erad       Date:  2018-07-01

2.  Optimising opioid substitution therapy in the prison environment.

Authors:  Farrukh Alam; Nat Wright; Paul Roberts; Sunny Dhadley; Joanne Townley; Russell Webster
Journal:  Int J Prison Health       Date:  2019-12-05

3.  Substance use characteristics, health risk practices and associated factors among people imprisoned in Catalonia: a cross-sectional study.

Authors:  E Bañuls-Oncina; R Clua-García; M Imbernón Casas; R Jiménez-Vinaja
Journal:  Rev Esp Sanid Penit       Date:  2019

4.  The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases.

Authors:  Heino Stöver; Anna Tarján; Gergely Horváth; Linda Montanari
Journal:  Harm Reduct J       Date:  2021-06-29

5.  Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.

Authors:  Rob Bielen; Samya R Stumo; Rachel Halford; Klára Werling; Tatjana Reic; Heino Stöver; Geert Robaeys; Jeffrey V Lazarus
Journal:  Harm Reduct J       Date:  2018-05-11

6.  Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.

Authors:  Sandra A Springer; Joshua A Barocas; Alysse Wurcel; Ank Nijhawan; Kinna Thakarar; Ruth Lynfield; Hermione Hurley; Jessica Snowden; Alice Thornton; Carlos Del Rio
Journal:  J Infect Dis       Date:  2020-09-02       Impact factor: 5.226

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.